Alkavervir

CHEMBL1201658 Phase 4 Disetujui Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A purified alkaloid extract from veratrum plants that was historically used to lower blood pressure by reducing heart rate and cardiac output through activation of cardiovascular reflexes. Due to its narrow therapeutic window and significant side effects, it has largely been replaced by safer modern antihypertensive medications.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A purified alkaloid extract from veratrum plants that was historically used to lower blood pressure by reducing heart rate and cardiac output through activation of cardiovascular reflexes. Due to its narrow therapeutic window and significant side effects, it has largely been replaced by safer modern antihypertensive medications.

Yes, Alkavervir is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201658. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Mencari informasi yang ramah bagi pasien?

Alkavervir di PillFYI

Data Cepat

Tautan Eksternal

ChEMBL CHEMBL1201658

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.